Flex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
resignation as the President and Chief Executive Officer of Flex
Pharma, Inc. (the “Company”), effective July 3, 2017. Dr.
Westphal will remain the Chairman of the Company’s Board of
Directors. William McVicar, Ph.D., the Company’s current
President, Research Development will replace Dr. Westphal as the
Company’s interim President and Chief Executive Officer on July
3, 2017. Information regarding Dr. McVicars business experience
is included in the Company’s Form 8-K filed with the Securities
and Exchange Commission on April 5, 2017 (File No. 001-36812),
which is incorporated herein by reference. There are no
arrangements or understandings between Dr. McVicar and any other
person to which he was appointed as interim Chief Executive
Officer. Dr. McVicar has no family relationships with any of the
Companys directors or executive officers, and he has no direct or
indirect material interest in any transaction required to be
disclosed to Item 404(a) of Regulation S-K. The Company’s Board
of Directors is evaluating Dr. McVicars compensation arrangements
as a result of his appointment as interim Chief Executive
Officer.
Stockholders at the offices of Cooley LLP, located at 500
Boylston Street, Boston, MA 02116 at 11:00 a.m. local time (the
“Annual Meeting”). At the Annual Meeting, the Company’s
stockholders voted on two proposals, each of which is described
in more detail in the Company’s definitive proxy statement on
Schedule 14A filed with the U.S. Securities and Exchange
Commission on April 19, 2017. The following is a brief
description of each matter voted upon, and the certified results,
including the number of votes cast for and against each matter
and, if applicable, the number of abstentions and broker
non-votes with respect to each matter.
serve on the Company’s Board of Directors (the “Board”) until
the Annual Meeting of Stockholders in 2020 or until his
respective successor has been duly elected or qualified. The
voting results were as follows:
|
Director Name
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Mr. Robert Perez
|
12,042,138
|
489,340
|
1,347,513
|
|
Mr. Stuart Randle
|
12,031,421
|
500,057
|
1,347,513
|
Committee of the Board of Ernst Young LLP as the Company’s
independent registered public accounting firm for the year ending
December 31, 2017. The voting results were as follows:
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
13,866,305
|
11,535
|
1,151
|
|
About Flex Pharma, Inc. (NASDAQ:FLKS)
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.